Background
Review
Myofascial trigger points
Investigations of myofascial trigger points
Ultrasound imaging
Microdialysis
Electromyography
Infrared thermography
Magnetic resonance imaging
Migraine and myofascial trigger points
First author (year) | Blinding | Participants | Mean age (range) | Gender | Timing of recordings | Methods | Muscles | Main findings |
---|---|---|---|---|---|---|---|---|
Calandre (2006) [45] | None | 8 EMA 55 EMO 35 CMO 32 CTRLs (18 (56%) of these reported infrequent TTH) | 38.5 ± 13.5 (15–75) 41.4 ± 16.8 (21–83) | 9 M, 79F 13 M, 19F | Interictally | MTrP diagnosis by manual palpation with a pressure by no more than 4 kg. The number and location of trigger points in each patient were recorded. | Frontal, temporal, and superior trapezius muscles and suboccipital and occipital area | • 93.9% migraine patients reported referred pain. • The number of MTrPs correlated with frequency and duration of migraine attacks. |
Fernández-de-Las-Peñas (2006) [46] | Examiner blinded to diagnosis | 5 EMA 15 EMO 20 CTRLs | 33 ± 10 (17–57) 30 ± 8 (19–55) | 7 M, 13F 8 M, 12F | Interictally | MTrP diagnosis was performed following the criteria described by Simons et al. [19] and by Gerwin et al. [89] FHP was documented in relaxed standing position and relaxed sitting position. Neck mobility was assessed. | Upper trapezius, sternocleidomastoid, temporalis, and subocciptal muscles | • Active MTrPs were only found in the migraine patients. • Active MTrPs were primarily located ipsilateral to the migraine headaches except for the suboccipital region. • Migraine patients have a greater FHP and less neck motility in extension and flexion-extension compared to controls. |
Ferracini (2017) [47] | Examiner blinded to diagnosis | 98 EM 45 CM With or without aura not reported. | 37 ± 12 (18–60) 38 ± 12 (18–60) | 143F | Interictally | MTrP diagnosis was performed following the criteria described by Simons et al. [19] and by Gerwin et al. [89] The Migraine Disability Assessment Scale (MIDAS) questionnaire was used. | Temporalis, masseter, suboccipital, sternocleidomastoid, upper trapezius and splenius capitis | • No significant difference was in the total number of MTrPs between the two groups. • Active MTrPs in the temporalis and masseter muscle were most prevalent in both groups. • The number of MTrPs did not correlate with migraine related disability nor migraine features. |
Ferracini (2016) [48] | None | 50 EM With or without aura not reported. | 34.1 (18–55) | 5 M, 45F | Interictally: 46% Ictally: 54% | MTrP diagnosis was performed following the criteria described by Simons et al. [19] and by Gerwin et al. [89] Eight measures of head and neck posture were obtained by radiograph and different angles were defined. | Temporalis, masseter, suboccipital, sternocleidomastoid,, upper trapezius, and splenius capitis | • Individuals with migraine showed MTrPs in all the muscles. • Active MTrPs was positively associated with a reduction in cervical lordosis and head extension of the head on the neck. • No association between the number of active MTrPs and clinical features of migraine was observed. |
Florencio (2017) [49] | None | 70 EMO | 42 ± 12 (39–45) | 70F | Interictally | MTrP diagnosis was performed following the criteria described by Simons et al. [19] and by Gerwin et al. [89] Surface EMG was recorded from superficial flexor and extensor muscles bilaterally as subjects performed a staged task of cranio-cervical flexion. The average Root Mean Square (RMS) was calculated from each 10 s contraction. | Sternocleidomastoid, upper trapezius and splenius capitis | • All patients exhibited active MTrPs in their cervical muscles • Participants with active MTrPs in the included muscles had lower normalized RMS in their superficial neck flexors • Subjects with active MTrPs in the splenius capitis and upper trapezius had higher normalized RMS values in the splenius capitis. |
Gandolfi (2017) [50] | Single-blind | 22 CM patients receiving onabotulinumtoxinA treatment Patients were divided into two groups: 12 individuals receiving manipulative treatment 10 individuals receiving electrical stimulation (placebo group) With or without aura not reported. | 45.8 ± 14.1 (18–66) 50.2 ± 6.2 (40–61) | 3 M, 19F 2 M, 10F 1 M, 9F | Not reported | Patients were randomly assigned to receive either manipulative treatment (treatment aimed at improving mobility and reducing stiffness in the cervicothoracic spine) or transcutaneous electrical nerve stimulation in the upper trapezius. Treatment consisted of 4 sessions (30 min once a week in 4 weeks) Patients were asked to keep a headache diary: outcomes were evaluated before treatment, during treatment, and 1 month after the end of treatment. Cervical active range of motion and trigger point sensitivity were measured pre- and posttreatment. MTrP sensitivity was assessed by measuring PPT using an algometer. | Frontalis, temporalis, occipital, and trapezius | • The total consumption of analgesics and NSAIDs was significantly lower in the patients treated with manipulative treatment than in those treated with electrical stimulation. • The PPTs at the MTrPs in the upper trapezius, occipital and temporal muscles were significantly lower in the patients treated with manipulative treatment than in those treated with electrical stimulation. • After trial patients who received manipulative treatment had a significantly lower consumption of NSAIDs, analgesics and triptans. |
Ghanbari (2015) [51] | None | 44 migraine patients Whether patients had chronic or episodic migraine with or without aura was not reported. | 37.25 38.63 35.86 Range not reported | 20 M, 24F 9 M, 13F 11 M, 11F | Not reported | MTrPs were considered to be active if 1) referred pain due to palpation reproduced the subjects’ headache. 2) There was a jump sign that was the characteristic behavioral response to pressure on a trigger point. All subjects included had active trigger points. Subjects (al were randomly assigned to one of two groups: 1) Medication only 2) Medication + positional release therapy The treatment phase lasted 2 weeks and medication included NSAIDs, nortriptyline, propranolol and depakine. Subjects completed a daily headache diary throughout the study and tablet count was recorded. After a baseline period of 2 weeks the sensitivity of trigger points (using a digital force gauge) and cervical range of motion were assessed. This was repeated after the treatment phase and as a follow up after 1, 2 and 4 months (counting from start of treatment) | Suboccipital, sternocleidomastoid, upper trapezius, cervical multifidus, rotators and interspinales | • Both groups showed significant reduction in headache intensity, frequency, duration and tablet count after 4 months follow up. • The sensitivity of trigger points was significantly reduced in the medication positional release therapy group, while it remained unchanged in the medicine only group. |
Giamberardino (2007) [52] | Examiner blinded to diagnosis | Primary experiment 78 MO (7 also diagnosed with TTH) 20 healthy CTRLs Secondary experiment 12 MO (2 also diagnosed with TTH) | 31.4 ± 5.8 (23–46) 33.3 ± 7 (18–46) 29.3 ± 4 (24–35) 32.33 ± 6.44 (24–44) | 11 M, 43F 5 M, 19F 5 M, 15F 3 M, 9F | Interictally | MTrP diagnosis was performed following the criteria described by Simons et al. [19] A MTrP was considered active if palpation induced both local and referred pain. Pain threshold was assessed by electrical stimulation. Subsequent to threshold measurements group 1 also received 0,5 mL bupivacaine (5 mg/mL). The infiltration and pain threshold measurements were repeated on the 3., 10., 30., and 60. day. PPT in healthy controls was assessed with the same frequency. Migraines (number and intensity of attacks) were assessed 60 days prior to the study and 60 days after the study started. This was done using a headache diary. The second study is a 30 days “placebo-like study” where saline was injected near the MTrPs. PPT, injections and the headache diary were fulfilled similarly to the the prior experiment. (only up till 30 days) | Sternocleidomastoid, semispinalis cervicis, splenius cervicis | • Group 1 and 2 pain thresholds were significantly lower than in controls at baseline. In group one pain threshold increased significantly during treatment. In group two there was no significant change. In the control group there was no significant variation. • In group 1 maximal intensity and number of migraine attacks decreased significantly. In group 2 the change was not significant. • The mean number of rescue medication taken fell significantly in group 1, but not in group 2. • The group that participated in the second experiment also had a pain threshold lower than normal. |
Landgraf (2017) [53] | None | 26 adolescent migraine patients (chronic/episodic not reported) 17 MO 5 MA 4 with vestibular migraine | 14.5 (6.3–17.8) | 13 M, 13F | Not specified | MTrPs were identified by palpation and the PPT on these points was measured using an algometer. Manual pressure was applied to the trigger points, and the occurrence and duration of induced headache were recorded. At a second consultation (4 weeks after the first), manual pressure with the detected pressure threshold was applied to non-trigger points within the same trapezius muscle (control). | Trapezius muscle | • Manual pressure to MTrPs in the trapezius muscle led to lasting headache after termination of the manual pressure in 13 (50%) patients (from 5 s to over 30 min). • No patient experienced headache when manual pressure was applied to non-trigger points at the control visit. • Headache was induced significantly more often in children ≥12 years and those with internalizing behavioral disorder. |
Landgraf (2015) [54] | None | 3 migraine patients Whether patients had chronic or episodic migraine with or without aura was not reported. | 23.67 (23–24) | 1 M, 2F | Interictally | MTrP diagnosis was performed following the criteria described by Simons et al. [19] and by Gerwin et al. [89] These areas were marked by nitroglycerin capsules on the adjacent skin surface. High-resolution MR imaging of the posterior cervico-cranial muscles was performed on a 3 T MR scanner with a spine array as well as surface coils. High resolution T2 weighted and T1-weighted sequences as well as short tau inversion recovery (STIR) sequences were acquired in a coronaland axial slice orientation. | Trapezius | • MR imaging demonstrated focal, partly T2 hyper intense signal alterations within the trapezius muscles in all three study participants. All of the observed signal alterations were in close proximity to the fiducial markers taped on the skin. |
Palacios-Ceña (2017) [55] | None | 95 EM With or without aura not reported. | 40 (37–43) | 0 M, 95F | Interictally | MTrP diagnosis was performed following the criteria described by Simons et al. [19]. PPT was assessed using an algometer.in the following regions: • Over the temporalis muscle. • C5/C6 zygapophyseal joint. • Tibialis anterior muscle (a pain-free distant control site) | Temporalis, masseter, suboccipital, sternocleidomastoid, upper trapezius, and splenius capitis | • The higher the intensity of migraine pain, the lower the PPTs over the cervical spine. • The number of active MTrPs was significantly and negatively associated with PPT in all the points. |
Ranoux (2017) [56] | None | 7 CMA 50 CMO 57 chronic migraine patients (refractory to conventional treatment) | 44.3 (17–85) | 14 M, 43F | Not specified | Observational, open label, real-life, cohort study. The patients were injected with OnabotulinumtoxinA using a “follow-the-pain” pattern in MTrPs. | Corrugator supercilii, temporalis and trapezius muscles | • 65.1% responded to treatment. • The associated cervical pain and muscle tenderness, present in 33 patients, was reduced by ≥50% in 31 patients (94%). • Triptan consumption decreased (81%) in responders. |
Sollmann (2016) [57] | None | 6 MO 14 MA (50% also had some degree of TTH) chronic/episodic not reported | 23 ± 1.8 (19–27) | 1 M, 19F | Interictally | rPMS (repetitive peripheral magnetic stimulation) was used to stimulate active MTrPs of the upper trapezius muscles. This was done in 6 stimulation sessions over 2 consecutive weeks. PPT was assessed using an algometer. Participants completed a standardized headache questionnaire including occurrence, duration and intensity of headaches. This was repeated over 3 months. | Trapezius and deltoid (as a control) | • In 19 subjects MTrP algometry values were significantly higher immediately after magnetic stimulation. • PPT increased during the trial. |
Tali (2014) [58] | Examiner blinded to diagnosis during upper cervical fact joint mobility/stiffness MTrP evaluation not blinded | 20 EM 20 CTRLs Distribution of with/without aura not reported. | 24.95 ± 1.79 (20–27) 25.65 ± 1.42 (23–28) | 2 M, 18F 3 M, 17F | Interictally | MTrP diagnosis Neck range of motion was assessed using a cervical range of motion instrument. FHP was noted in a seated position. Upper cervical facet joint mobility/stiffness was evaluated using a motion palpation technique. | Sternocleidomastoid and upper trapezius muscle | • Active MTrPs were only found in the migraine group. • Significant differences were found in neck range of motion measurements and FHP between the migraine and control groups. |
The occurrence of myofascial trigger points in migraine
Neck mobility and specific muscles
Provocation and intervention studies
Tension-type headache and myofascial trigger points
First author (year) | Blinding | Participants | Mean age (range) | Gender | Timing of recordings | Methods | Muscles | Main findings |
---|---|---|---|---|---|---|---|---|
Alonso-Blanco (2011) [62] | None | 20 CTTH adult patients 20 CTTH adolescent patients | 41 (18–47) 8 (6–12) | 10 M, 10F 10 M, 10F | Interictally | MTrP diagnosis as described by Simons et al. [19] | Temporalis, suboccipital, sternocleidomastoid, and upper trapezius | • The number of active MTrPs were higher in adults versus children. • Referred pain elicited from active MTrPs shared similar pain patterns as spontaneous CTTH in both groups. No significant association between the number of active MTrPs and headache parameters. |
Couppé (2007) [67] | Double-blinded | 20 CTTH patients 20 CTRLs | 37.5 (33.3–41.6) | Not reported | Ictally | MTrP diagnosis as described by Simons et al. [19] EMG examination at a MTrP and a control point in the same subject. | Upper trapezius | • The number of active MTrPs were higher in patients versus controls • No difference in electromyographic activity between MTrPs versus control points. |
Fernández-de-las-Peñas (2011) [63] | Examiner blinded to diagnosis | 50 CTTH patients 50 CTRLs | 8 (6–12) | 14 M, 36F | Interictally | MTrP diagnosis as described by Simons et al. [19]. | Temporalis, superior oblique, masseter, suboccipital, sternocleidomastoid, levator scapulae, and upper trapezius | • Active MTrPs were only found in patients. • In the CTTH patients, the number of active TrPs correlated with the duration of a headache attack. • The local and referred pains elicited from active MTrPs shared similar pain pattern as spontaneous CTTH. |
Fernández-de-las-Peñas (2009) [68] | None | 40 CTTH | 40 (20–57) | 40F | Interictally < 4 on a 11 NRS | MTrP diagnosis was performed following the criteria described by Simons et al. [19] and Gerwin et al. [89] PPT was assessed using an algometer. | Temporalis (9 landmarks total, 3 each respectively in the anterior, medial and posterior part) | • The analysis of variance did not detect significant differences in the referred pain pattern between active MTrPs. • The topographical pressure pain sensitivity maps showed the distinct distribution of the MTrPs indicated by locations with low PPTs. |
Fernández-de-las-Peñas (2007) [69] | Examiner blinded to diagnosis | 15 ETTH 15 CTRLs | 39 ± 17 (20–70) 37 ± 12 (21–70) | 3 M, 12F 4 M, 11F | Interictally | FHP was noted both seated and standing. | Temporalis, sternocleidomastoid, and upper trapezius | • Active MTrPs in the affected muscles were only found within the ETTH group. • MTrPs were not related to any clinical variable concerning the intensity and the temporal profile of headache. |
Fernández-de-las-Peñas (2007) [70] | Examiner blinded to diagnosis | 20 CTTH 20 CTRLs | 36 (18–56) 35 (20–56) | 11 M, 9F 13 M, 7F | < 4 cm on a 10 cm VAS | PPT was assessed using an algometer. | Upper trapezius | • CTTH subjects with active MTrPs showed greater headache intensity, and duration than those with latent TrPs. • Patients with bilateral MTrPs reported a greater headache intensity and duration than those with unilateral TrPs. • CCTH subjects showed a decreased PPT compared to controls. |
Fernández-de-las-Peñas (2007) [66] | Examiner blinded to diagnosis | 30 CTTH 30 CTRLs | 39 ± 16 (18–65) 39 ± 12 (19–65) | 9 M, 21F 9 M, 21F | < 4 cm on a 10 cm VAS | Temporalis | • Referred pain was evoked in 87 and 54% on the dominant and non-dominant sides in CTTH patients, which was significantly higher than in controls (10% vs. 17%, respectively). • CTTH patients with active MTrPs in either right or left temporalis muscle showed longer headache duration than those with latent MTrPs. • CTTH patients showed significantly lower pressure pain threshold when compared with controls. | |
Fernández-de-las-Peñas (2006) [71] | Examiner blinded to diagnosis | 10 ETTH 10 CTRLs | 35 ± 15 (18–66) 34 ± 13 (18–66) | 2 M, 8F 3 M, 7F | Interictally | Suboccipital | • In the ETTH group, 60% showed active MTrPs; 40% showed latent trigger points. In the ETTH group, headache intensity, frequency and duration did not differ depending on whether the MTrPs were active or latent. | |
Fernández-de-las-Peñas (2006) [72] | Examiner blinded to diagnosis | 25 CTTH 25 CTRLs | 40 ± 16 (18–72) 38 ± 9 (18–73) | 8 M, 17F 9 M, 16F | < 4 cm on a 10 cm VAS | MTrP diagnosis was performed following the criteria described by Simons et al. [19] and by Gerwin et al. [89] FHP was noted both seated and standing. | Temporalis, sternocleidomastoid, and upper trapezius | • Active MTrPs were only found in CTTH patients. • There was significant association between the presence of active MTrPs and headache intensity and duration. |
Fernández-de-las-Peñas (2006) [65] | Examiner blinded to diagnosis | 20 CTTH 20 CTRLs | 38 ± 18 (18–70) 35 ± 10 (20–68) | 9 M, 11F 12 M, 8F | Pain intensity < 4 on a 10 cm VAS | MTrP diagnosis was performed following the criteria described by Simons et al. [19] and by Gerwin et al. [89] FHP was noted both seated and standing. | Suboccipital | • Active MTrPs were only found in CTTH patients. • CTTH patients with active MTrPs reported greater headache intensity and frequency than those with latent. • A craniovertebral smaller angle was positively correlated with increased headache frequency and negatively correlated with headache duration. |
Fernández-de-las-Peñas (2005) [64] | Examiner blinded to diagnosis | 15 CCTH 15 ETTH 15 CTRLs | 37 ± 16 38 ± 14 38 ± 14 Range not reported | 5 M, 10F 4 M, 11F 5 M, 10F | CTTH: Pain intensity < 4 cm on a 10 cm VAS TTH: Interictally | Superior oblique | • 86% CTTH patients and 60% ETTH patients reported referred pain from MTrPs. • The pain was perceived as a deep ache located at the retro-orbital region – sometimes extending to the supraorbital region or the homo-lateral forehead. • Pain intensity was greater in CTTH patients than in ETTH patients. | |
Harden (2009) [73] | Double-blinded | 23 CTTH with active cervical MTrPs (12 in active group, 11 in placebo group) | 49.6 in active group 40.8 in placebo group Range not reported | 7 M, 5F 7 M, 4F | Not reported | Patients received i.m. injections of botulinum toxin A or isotonic saline (placebo) in MTrPs. 25 units dose pr. MTrP, but no more than 100 units in total pr. patient (maximum four trigger points treated pr. patient). | Sternocleidomastoid, trapezius, and splenius capitis (which overlies involved cervical muscle groups: semispinalis capitis, longissimus capitis, recti capitis posterior and obliquus capitis superior) | • Patients in the active group reported greater reductions in headache frequency during the first part of the study, but these effects dissipated by week 12. |
Karadas (2013) [74] | Double-blinded | 48 CTTH with active MTrPs (24 in active group, 24 in placebo group). | 40.4 ± 12 in active group 40.7 ± 13.2 in placebo group Range not reported | 4 M, 20F 5 M, 19F | Not reported | Patients received i.m. injections with 0.5% lidocaine or 0.9% NaCl (placebo) to the trigger points of the muscles innervated by C1-C3 and the trigeminal nerve, exit point of the fifth cranial nerve and around the superior cervical ganglion. | Muscles innervated by C1-C3 and the trigeminal nerve, exit point of the fifth cranial nerve and around the superior cervical ganglion | • Patients in the active group reported significantly greater reductions in headache frequency and intensity. |
Lattes (2009) [75] | None | 27 CTTH | Approximately 46 (18–80) | 7 M, 20F | Not reported | I.m. injections with gonyautoxin in 10 landmarks considered as MTrPs. EMG examination before and after injections. | Occipitalis and trapezius | • Responders (70%) had an average of 8,1 weeks free of pain following treatment. • The EMG recorded immediately after injection in all cases showed that the hyperactivity in the trapezius muscle was completely abolished. |
Moraska (2017) [76] | Single-blind | 34 CTTH 28 ETTH Massage: 13 CTTH 7 ETTH Placebo: 11 CTTH 10 ETTH Wait-list 10 CTTH 11ETTH | 31.2 ± 11.3 34.4 ± 10.7 33.0 ± 9.0 | 7 M, 55F 1 M, 19F 2 M, 19F 4 M, 17F | Not reported | Individuals with ETTH or CTTH were randomized to receive 12 twice-weekly 45-min massage or sham ultrasound sessions or wait-list control. Massage focused on MTrPs. PPT was assessed using an algometer. MTrP diagnosis was performed following the criteria described by Simons et al. [19] | Suboccipital and upper trapezius | • PPT increased across the study timeframe in all four muscle sites tested for massage, but not sham ultrasound or wait-list groups. |
Moraska (2015) [77] | Single-blind | 30 CTTH 26 ETTH | 32.1 ± 12 in active group 34.7 ± 11 in placebo group Range not reported | 8 M, 48F (2 M, 15F in active group; 2 M, 17F in placebo group; 4 M, 16F in wait-list group) | Not reported | 56 patients with TTH were randomized to receive 12 massage or placebo (detuned ultrasound) sessions over 6 weeks, or to wait-list. Massage focused on MTrPs in cervical musculature. PPT was assessed using an algometer. MTrP diagnosis was performed following the criteria described by Simons et al. [19] | Suboccipital, sternocleidomastoid, and upper trapezius | • Headache frequency fell in both the massage and the placebo group. • PPT improved in the massage group. |
Palacios-Ceña (2016) [78] | Examiner blinded to diagnosis | 77 CTTH 80 ETTH | 46 (42–50) 47 (43–51) | 46 M, 111F | Interictally | MTrP diagnosis was performed following the criteria described by Simons et al. [19] PPT was assessed over the trigeminal area, extra-trigeminal area and two distant pain free points using an algometer. | Temporalis, masseter, suboccipital, sternocleidomastoid, splenius capitis, and upper trapezius | • No difference in number of MTrPs and PPT in the two groups. • There was a significant negative correlation between the number of trigger points (active or latent) and PPT. |
Romero-Morales (2017) [79] | None | 60 ETTH 60 CTRLs | 38,30 ± 10,05 34 ± 8,20 Range not reported | 24 M, 32F 27 M, 33F | Not reported | MTrP diagnosis was performed following the criteria described by Simons et al. [19] PPT was assessed using an algometer. | Temporalis and upper trapezius | Minimum clinical differences in PPT between TTH and CTRLs were • Right upper trapezius; 0,85 kg/cm2 • Left upper trapezius; 0;76 kg/cm2 • Right temporalis; 0;16 kg/cm2 • Left temporals; 0,17 kg/cm2 |
Sohn (2012) [80] | Examiner blinded to diagnosis | 23 CTTH 36 ETTH 42 CTRLs | 53.43 ± 16.97 51.11 ± 14.42 51.69 ± 16.18 Range not reported | 2 M, 21F 7 M, 29F 8 M, 34F | Headache intensity < 3 on a 10 cm VAS | MTrP diagnosis was performed following the criteria described by Simons et al. [19] and by Gerwin et al. [89] FHP was used to evaluate posture abnormalities. Measurement of neck mobility was used to evaluate mechanical abnormalities. | Temporalis, suboccipital, sternocleidomastoid, and upper trapezius | • The number of active MTrPs was significantly greater in CTTH subjects than in ETTH subjects. • The number of active MTrPs were correlated with the frequency and duration of headache. • No correlations were observed for FHP or neck mobility. |
The occurrence of myofascial trigger points in tension-type headache
Neck mobility and specific muscles
Pressure pain threshold
Therapeutic studies targeting myofascial trigger points
Discussion
Migraine | Tension-type headache | Total | |
---|---|---|---|
Blinding | 36% (5/14 relevant studies) | 79% (15/19 relevant studies) | 61% (19/33 relevant studies) |
Control group | 44% (4/9 relevant studies) | 79% (11/14 relevant studies) | 65% (15/23 relevant studies) |
Placebo | 40% (2/5 relevant studies) | 80% (4/5 relevant studies) | 60% (6/10 relevant studies) |